Literature DB >> 6199633

Neurotensin secretion by fibrolamellar carcinoma of the liver.

N A Collier, K Weinbren, S R Bloom, Y C Lee, H J Hodgson, L H Blumgart.   

Abstract

Serum neurotensin concentrations were supranormal in 5 out of 20 patients with carcinoma of the liver. Liver specimens from 4 of these 5 patients demonstrated features typical of fibrolamellar carcinoma. Neurotensin may be suitable as a tumour marker for fibrolamellar carcinoma and may be useful for the detection of recurrences after treatment.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6199633     DOI： 10.1016/s0140-6736(84)90934-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  34 in total

1.  Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.

Authors:  A D Pinna; S Iwatsuki; R G Lee; S Todo; J R Madariaga; J W Marsh; A Casavilla; I Dvorchik; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

2.  A young woman with liver cancer.

Authors:  Celina S Ang; Richard K Do; Ali Shamseddine; Eileen M O'Reilly; Ali Haydar; Ashwaq Al-Olayan; Walid Faraj; Fouad Boulos; Mohamed Naghy; Dorothy Makanjoula; Hassan Farran; Hassan Sibai; David Wehbe; David P Kelsen; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

3.  Genomic analysis of fibrolamellar hepatocellular carcinoma.

Authors:  Lei Xu; Florette K Hazard; Anne-Flore Zmoos; Nadine Jahchan; Hassan Chaib; Phillip M Garfin; Arun Rangaswami; Michael P Snyder; Julien Sage
Journal:  Hum Mol Genet       Date:  2014-08-13       Impact factor: 6.150

4.  Genomic homogeneity in fibrolamellar carcinomas.

Authors:  Y Sirivatanauksorn; V Sirivatanauksorn; N R Lemoine; R C Williamson; B R Davidson
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

5.  Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells.

Authors:  Yanli Zhang; Shunqin Zhu; Liang Yi; Yaling Liu; Hongjuan Cui
Journal:  Mol Cell Biochem       Date:  2013-12-20       Impact factor: 3.396

6.  Late supra-diaphragmatic lymph node recurrence following resection of a fibrolamellar hepatocarcinoma: an unusual case.

Authors:  Basile Tsilividis; Emmanuel Huet; Jean Lubrano; Laurence Lacaze; Jean Pierre Lestrat; Arnaud François; Ghassan Riachi; Michel Scotté
Journal:  Surg Radiol Anat       Date:  2009-09-24       Impact factor: 1.246

7.  Distinct immunohistochemical findings in columnar epithelium of esophageal inlet patch and of Barrett's esophagus.

Authors:  G E Feurle; V Helmstaedter; A Buehring; U Bettendorf; V F Eckardt
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

Review 8.  Fibrolamellar hepatocellular carcinoma coexistent with a hepatocellular carcinoma of common type: report of a case.

Authors:  K Okada; Y I Kim; K Nakashima; I Tada; T Yoshida; M Kobayashi; S Yokoyama
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

9.  Aggressive surgical management of fibrolamellar hepatocellular carcinoma.

Authors:  A W Hemming; B Langer; P Sheiner; P D Greig; B R Taylor
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

10.  Fibrolamellar carcinoma of the liver--a case report.

Authors:  T Imai; H Yokoi; T Noguchi; Y Kawarada; R Mizumoto
Journal:  Gastroenterol Jpn       Date:  1991-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.